Ofatumumab — Membership Pricing
Ofatumumab is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Ofatumumab Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $101.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Ofatumumab
Ofatumumab is a prescription medication. Ask your doctor if Ofatumumab is right for you.
How to Check Ofatumumab Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Ofatumumab at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
What Ofatumumab is approved for (FDA label)
KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: April 1, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Ofatumumab (FDA label)
KESIMPTA is a clear to slightly opalescent, and colorless to slightly brownish-yellow solution available as follows: Injection: 20 mg/0.4 mL in a single-dose prefilled Sensoready Pen Injection: 20 mg/0.4 mL in a single-dose prefilled syringe Injection: 20 mg/0.4 mL solution in a single-dose prefilled Sensoready ® Pen ( 3 ) Injection: 20 mg/0.4 mL solution in a single-dose prefilled syringe ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 6a8a3f53-2062-48ff-9dbe-b939df133ca3. SPL document ID: ab75831e-d802-456a-bae6-7c85ef8dc3ed. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Ofatumumab (FDA label)
The following clinically significant adverse reactions are discussed in greater detail elsewhere in the labeling: Infections [see Warnings and Precautions (5.1)] Injection-Related Reactions and Hypersensitivity Reactions [see Warnings and Precautions (5.2)] Reduction in Immunoglobulins [see Warnings and Precautions (5.3)] Liver Injury [see Warnings and Precautions (5.4)] Most common adverse reactions (incidence greater than 10%) are upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Source: FDA prescribing information (DailyMed). Set ID: 6a8a3f53-2062-48ff-9dbe-b939df133ca3. SPL document ID: ab75831e-d802-456a-bae6-7c85ef8dc3ed. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Ofatumumab (FDA label)
KESIMPTA is contraindicated in patients with: Active HBV infection [see Warnings and Precautions (5.1)] . History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.2)] . Active HBV infection. ( 4 ) History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 6a8a3f53-2062-48ff-9dbe-b939df133ca3. SPL document ID: ab75831e-d802-456a-bae6-7c85ef8dc3ed. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Ofatumumab (FDA label)
Infections: Serious, including life-threatening and fatal infections, have occurred in patients treated with anti-CD20 therapies. Delay KESIMPTA administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with KESIMPTA and after discontinuation, until B-cell repletion. ( 5.1 ) Injection-Related Reactions and Hypersensitivity Reactions: Management for injection-related reactions and hypersensitivity reactions depends on the type and severity of the reaction. ( 4 , 5.2 ) Reduction in Immunoglobulins: Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with KESIMPTA until B-cell repletion. Consider discontinuing KESIMPTA if a patient develops a serious opportunistic infection or recurrent infections if immunoglobulin levels indicate immune compromise. ( 5.3 ) Liver Injury: Clinically significant liver injury has occurred. Obtain serum aminotransferases, alkaline phosphatase, and bilirubin levels before initiating KESIMPTA, and during treatment as clinically indicated.
Source: FDA prescribing information (DailyMed). Set ID: 6a8a3f53-2062-48ff-9dbe-b939df133ca3. SPL document ID: ab75831e-d802-456a-bae6-7c85ef8dc3ed. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Ofatumumab (FDA label)
7.1 Immunosuppressive or Immune-Modulating Therapies Concomitant usage of KESIMPTA with immunosuppressant drugs, including systemic corticosteroids, may increase the risk of infection. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with KESIMPTA. When switching from therapies with immune effects, the duration and mechanism of action of these therapies should be taken into account because of potential additive immunosuppressive effects when initiating KESIMPTA.
Source: FDA prescribing information (DailyMed). Set ID: 6a8a3f53-2062-48ff-9dbe-b939df133ca3. SPL document ID: ab75831e-d802-456a-bae6-7c85ef8dc3ed. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.